StockNews.com Begins Coverage on Organovo (NASDAQ:ONVO)

Analysts at StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a research note issued on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Price Performance

Shares of Organovo stock opened at $1.72 on Friday. Organovo has a 1 year low of $1.56 and a 1 year high of $21.96. The stock has a market cap of $2.93 million, a price-to-earnings ratio of -2.02 and a beta of 1.13. The firm’s 50-day moving average is $4.14 and its two-hundred day moving average is $4.63.

Organovo (NASDAQ:ONVO) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($2.28) EPS for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.24. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. On average, equities analysts expect that Organovo will post -0.77 earnings per share for the current year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.